Abstract
PurposeThe aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with 177Lu‐DOTATATE (LUTATHERA®).MethodsThe dosimetric analysis was performed on two patients during two cycles of PRRT with 177Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit® (DTK) from Xeleris™ and HybridRecon‐Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time‐integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations.ResultsThe majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms.ConclusionsWhen applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms.
Highlights
Dosimetry contributes to the evaluation of the outcome and the optimization process of targeted radionuclide therapy
We present results of the comparison of five commercial software applications, based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE (LUTATHERA®), based on three evaluation criteria: organ masses, time-integrated activity coefficient (TIAC), and mean absorbed doses
The objective of this study was to compare the results generated by five commercial dosimetry software platforms
Summary
Dosimetry contributes to the evaluation of the outcome and the optimization process of targeted radionuclide therapy. Peptide receptor radionuclide therapy (PRRT) optimization can be based on the evaluation of absorbed doses delivered to critical organs, such as kidneys and red or active bone marrow.[1,2,3,4,5] Different approaches to clinical dosimetry have been proposed, based on whole body (WB) planar images,[6,7,8,9] single photon emission computed tomography/ computed tomography (SPECT/CT) images,[10,11,12,13] and hybrid methods by combining WB planar images with one or two SPECT/CT scans.[14,15,16,17,18]. Imaging and data processing methodology have historically been predominantly specific to each institution, because there were no commercial software applications available to perform all aspects of clinical dosimetry. Other software are available or have been announced recently (QDOSE31)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call